Get the Stockscreener App
3.065
2.24%
-0.065
After Hours:
3.04
-0.025
-0.82%
Protara Therapeutics Inc stock is traded at $3.065, with a volume of 300.21K.
It is down -2.24% in the last 24 hours and down -12.57% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$3.13
Open:
$3.13
24h Volume:
300.21K
Relative Volume:
0.87
Market Cap:
$117.48M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-1.0869
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
-2.24%
1M Performance:
-12.57%
6M Performance:
+1.66%
1Y Performance:
+5.52%
1-Day Range:
$3.02
$3.1752
1-Week Range:
$3.02
$3.34
52-Week Range:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.045 | 122.30M | 0 | -42.05M | -35.26M | -2.82 |
|
ONC
Beone Medicines Ltd Adr
|
245.80 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Transcript : Protara Therapeutics, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 01 - marketscreener.com
Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation - Nasdaq
Protara Therapeutics (TARA) Initiates Coverage with a Buy Rating - GuruFocus
Protara Therapeutics (TARA) Initiates Coverage with a Buy Rating | TARA Stock News - GuruFocus
Protara Therapeutics (TARA) Receives Buy Rating with $21 Price T - GuruFocus
Jones Initiates Protara Therapeutics at Buy With $21 Price Target - marketscreener.com
Richard Levy Spends US$64k On Protara Therapeutics Stock - Yahoo Finance
BNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Dimensional Fund Advisors LP Makes New $111,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Richard Levy Bought 65% More Shares In Protara Therapeutics - simplywall.st
Insider Buying: Richard Levy Acquires 20,000 Shares of Protara T - GuruFocus
With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing - Yahoo Finance
Protara Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Buy” from Brokerages - Defense World
Protara Therapeutics Reports Q1 2025 Financial Results - TipRanks
Protara Therapeutics: Q1 Earnings Snapshot - New Haven Register
Barclays PLC Takes $492,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile - TipRanks
Protara (TARA) Strengthens Leadership with Key Appointments | TA - GuruFocus
Protara Therapeutics (TARA) Sees Positive Results in TARA-002 Trial | TARA Stock News - GuruFocus
Protara (TARA) Strengthens Leadership with Key Appointments | TARA Stock News - GuruFocus
Protara Therapeutics Q1 2025 Financial Results and Business Update - TradingView
Protara Therapeutics, Inc. SEC 10-Q Report - TradingView
Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Geode Capital Management LLC Buys 9,553 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Renaissance Technologies LLC Sells 194,440 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Protara Therapeutics Expands Leadership Team: New CPO Receives 61,500 Equity Awards Amid Growth Push - Stock Titan
Stocks of Protara Therapeutics Inc (TARA) are poised to climb above their peers - Sete News
It would be worthwhile to take a closer look at Protara Therapeutics Inc (TARA) - uspostnews.com
Protara Therapeutics, Inc.'s (NASDAQ:TARA) institutional investors lost 14% last week but have benefitted from longer-term gains - simplywall.st
Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Sold by LPL Financial LLC - Defense World
The Potential Rise in the Price of Protara Therapeutics Inc (TARA) following insiders activity - knoxdaily.com
Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial - streetwisereports.com
Protara Therapeutics Inc Inc. (TARA) Price Performance: A Technical Analysis Perspective - investchronicle.com
Balance Sheet Breakdown: Protara Therapeutics Inc (TARA)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Protara Therapeutics (NASDAQ:TARA) Given “Buy” Rating at HC Wainwright - Defense World
Protara Therapeutics stock drops following interim trial results By Investing.com - Investing.com Nigeria
Protara Therapeutics stock drops following interim trial results - Investing.com Australia
Protara Therapeutics Inc (NASDAQ: TARA)’s Potential for Significant Price Increase in the Near Future - Marketing Sentinel
Protara Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Protara Therapeutics Announces Positive Interim Results Demonstr - GuruFocus
Protara Therapeutics Shares Positive Phase 2 Interim Results Of TARA-002 In Patients With NMIBC - Nasdaq
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protara Therapeutics Inc Stock (TARA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zummo Jacqueline | Chf Scientific Operations Off |
Mar 26 '25 |
Sale |
4.53 |
21,224 |
96,145 |
98,861 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):